A meta-analysis of individual patient data from the ACCENT database demonstrated that the combination of oxaliplatin plus fluoropyrimidine (FP) should be considered standard-of-care adjuvant therapy for patients with microsatellite instability or mismatch repair deficient (MSI/dMMR) stage III colon cancer.1
The study, published in the Journal of Clinical Oncology, also indicated that patients with colon cancer and MSI experienced better outcomes in the N1 group when compared with those with microsatellite stable (MSS) disease; however, both groups saw similar survival in the N2 group. Given these findings, the investigators suggested that N stage should be a stratification parameter in future trials dedicated to the MSI/dMMR population.
“As the current work is the largest ever published on adjuvant FP for patients with MSI stage III [colon cancer], it suggests that FP alone should not…
